Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro

Yoshinori Go, Shravan K. Chintala, Alan Rayford, Evangelin Gagercas, Francis Ali-Osman, Boyapati Venkaiah, Raymond Sawaya, Ziya Gokaslan, Garth L. Nicolson, J. S. Rao

Research output: Contribution to journalArticle

Abstract

Glioblastomas extensively invade the surrounding normal brain tissue, with a concomitant expression of various proteolytic enzymes, in particular urokinase-type plasminogen activator (uPA). In this study we used cisdiamminedichloroplatinum (cisplatin) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), commonly used anti-cancer drugs for the treatment of glioblastomas, to study the expression of uPA in three human glioblastoma cell lines in vitro. Cells were treated with 25 μM cisplatin and 50 μM BCNU, and uPA levels were estimated by fibrin zymography during a 72-h time course. Treatment of glioblastoma cells with cisplatin resulted in significantly decreased levels of uPA in serum-free conditioned medium and cell extracts, compared to BCNU-treated and untreated cell lines. Quantitative levels of uPA enzyme activity assessed by scanning laser densitometry and uPA protein by ELISA using antibody against uPA showed decreased levels of uPA in cisplatin-treated glioma cell lines relative to BCNU and untreated cell lines. Our results suggest that anti-tumor compound, cisplatin, may exert its anti-neoplastic effects by inhibiting uPA in malignant glioblastomas.

Original languageEnglish (US)
Pages (from-to)447-452
Number of pages6
JournalClinical and Experimental Metastasis
Volume15
Issue number4
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Carmustine
Urokinase-Type Plasminogen Activator
Glioblastoma
Cisplatin
Cell Line
Enzyme Activators
In Vitro Techniques
Densitometry
Serum-Free Culture Media
Conditioned Culture Medium
Cell Extracts
Fibrin
Glioma
Neoplasms
Lasers
Peptide Hydrolases
Enzyme-Linked Immunosorbent Assay
Antibodies

Keywords

  • BCNU
  • Cisplatin
  • Glioblastoma
  • Invasion
  • uPA

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. / Go, Yoshinori; Chintala, Shravan K.; Rayford, Alan; Gagercas, Evangelin; Ali-Osman, Francis; Venkaiah, Boyapati; Sawaya, Raymond; Gokaslan, Ziya; Nicolson, Garth L.; Rao, J. S.

In: Clinical and Experimental Metastasis, Vol. 15, No. 4, 1997, p. 447-452.

Research output: Contribution to journalArticle

Go, Y, Chintala, SK, Rayford, A, Gagercas, E, Ali-Osman, F, Venkaiah, B, Sawaya, R, Gokaslan, Z, Nicolson, GL & Rao, JS 1997, 'Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro', Clinical and Experimental Metastasis, vol. 15, no. 4, pp. 447-452. https://doi.org/10.1023/A:1018462507706
Go, Yoshinori ; Chintala, Shravan K. ; Rayford, Alan ; Gagercas, Evangelin ; Ali-Osman, Francis ; Venkaiah, Boyapati ; Sawaya, Raymond ; Gokaslan, Ziya ; Nicolson, Garth L. ; Rao, J. S. / Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. In: Clinical and Experimental Metastasis. 1997 ; Vol. 15, No. 4. pp. 447-452.
@article{e3b0fd839c284455ba30b1321ec98971,
title = "Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro",
abstract = "Glioblastomas extensively invade the surrounding normal brain tissue, with a concomitant expression of various proteolytic enzymes, in particular urokinase-type plasminogen activator (uPA). In this study we used cisdiamminedichloroplatinum (cisplatin) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), commonly used anti-cancer drugs for the treatment of glioblastomas, to study the expression of uPA in three human glioblastoma cell lines in vitro. Cells were treated with 25 μM cisplatin and 50 μM BCNU, and uPA levels were estimated by fibrin zymography during a 72-h time course. Treatment of glioblastoma cells with cisplatin resulted in significantly decreased levels of uPA in serum-free conditioned medium and cell extracts, compared to BCNU-treated and untreated cell lines. Quantitative levels of uPA enzyme activity assessed by scanning laser densitometry and uPA protein by ELISA using antibody against uPA showed decreased levels of uPA in cisplatin-treated glioma cell lines relative to BCNU and untreated cell lines. Our results suggest that anti-tumor compound, cisplatin, may exert its anti-neoplastic effects by inhibiting uPA in malignant glioblastomas.",
keywords = "BCNU, Cisplatin, Glioblastoma, Invasion, uPA",
author = "Yoshinori Go and Chintala, {Shravan K.} and Alan Rayford and Evangelin Gagercas and Francis Ali-Osman and Boyapati Venkaiah and Raymond Sawaya and Ziya Gokaslan and Nicolson, {Garth L.} and Rao, {J. S.}",
year = "1997",
doi = "10.1023/A:1018462507706",
language = "English (US)",
volume = "15",
pages = "447--452",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro

AU - Go, Yoshinori

AU - Chintala, Shravan K.

AU - Rayford, Alan

AU - Gagercas, Evangelin

AU - Ali-Osman, Francis

AU - Venkaiah, Boyapati

AU - Sawaya, Raymond

AU - Gokaslan, Ziya

AU - Nicolson, Garth L.

AU - Rao, J. S.

PY - 1997

Y1 - 1997

N2 - Glioblastomas extensively invade the surrounding normal brain tissue, with a concomitant expression of various proteolytic enzymes, in particular urokinase-type plasminogen activator (uPA). In this study we used cisdiamminedichloroplatinum (cisplatin) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), commonly used anti-cancer drugs for the treatment of glioblastomas, to study the expression of uPA in three human glioblastoma cell lines in vitro. Cells were treated with 25 μM cisplatin and 50 μM BCNU, and uPA levels were estimated by fibrin zymography during a 72-h time course. Treatment of glioblastoma cells with cisplatin resulted in significantly decreased levels of uPA in serum-free conditioned medium and cell extracts, compared to BCNU-treated and untreated cell lines. Quantitative levels of uPA enzyme activity assessed by scanning laser densitometry and uPA protein by ELISA using antibody against uPA showed decreased levels of uPA in cisplatin-treated glioma cell lines relative to BCNU and untreated cell lines. Our results suggest that anti-tumor compound, cisplatin, may exert its anti-neoplastic effects by inhibiting uPA in malignant glioblastomas.

AB - Glioblastomas extensively invade the surrounding normal brain tissue, with a concomitant expression of various proteolytic enzymes, in particular urokinase-type plasminogen activator (uPA). In this study we used cisdiamminedichloroplatinum (cisplatin) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), commonly used anti-cancer drugs for the treatment of glioblastomas, to study the expression of uPA in three human glioblastoma cell lines in vitro. Cells were treated with 25 μM cisplatin and 50 μM BCNU, and uPA levels were estimated by fibrin zymography during a 72-h time course. Treatment of glioblastoma cells with cisplatin resulted in significantly decreased levels of uPA in serum-free conditioned medium and cell extracts, compared to BCNU-treated and untreated cell lines. Quantitative levels of uPA enzyme activity assessed by scanning laser densitometry and uPA protein by ELISA using antibody against uPA showed decreased levels of uPA in cisplatin-treated glioma cell lines relative to BCNU and untreated cell lines. Our results suggest that anti-tumor compound, cisplatin, may exert its anti-neoplastic effects by inhibiting uPA in malignant glioblastomas.

KW - BCNU

KW - Cisplatin

KW - Glioblastoma

KW - Invasion

KW - uPA

UR - http://www.scopus.com/inward/record.url?scp=8544230593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544230593&partnerID=8YFLogxK

U2 - 10.1023/A:1018462507706

DO - 10.1023/A:1018462507706

M3 - Article

C2 - 9219734

AN - SCOPUS:8544230593

VL - 15

SP - 447

EP - 452

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 4

ER -